期刊
NPJ GENOMIC MEDICINE
卷 5, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41525-020-0124-5
关键词
-
资金
- General Research Fund (Research Grant Council, Hong Kong) [17114814]
- Research Grant Council, General Research Fund [17114814, 17121616, 14168517, R4017-18]
- Research Impact Fund
- Health and Medical Research Fund (HMRF, the Health and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region) [15160691]
- Hong Kong Cancer Fund, Hong Kong SAR
- School of Biomedical Sciences, Faculty of Medicine, CUHK
- National Cancer Institute, NIH, USA [1R01CA229836-01A1]
- Innovation and Technology Fund, Hong Kong government [PiH/052/18, PiH/234/18]
- Dr. Stanley Ho Medical Foundation
- General Research Fund, Research Grant Council, Hong Kong government, Hong Kong SAR [14109716, 14108818]
- HK RGC-GRF [17120718]
- University-Industry Collaboration Program (Innovation and Technology Fund, Hong Kong government, Hong Kong SAR) [UIM/329]
- University-Industry Collaboration Program (Lee's Pharmaceutical (HK) Limited) [UIM/329]
Head and neck squamous cell carcinoma (HNSCC) lacks predictive biomarkers for drug responses. By targeted sequencing, we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K. We previously reported an exceptional erlotinib responder with MAPK1p.E322K. Here, by in silico and drug studies, we determined functions of these two recurrence-associated MAPK1 mutations. Residues D321, R135, and E322 are in 3D proximity. MAPK1p.D321N drives marked in vivo erlotinib sensitivity, while p.R135K's effect is moderate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
